RE:For Not(e)able - pelareorep is an IMMUNE PLATFORM MOLECULEOncy's late stage development of its immune platform molecule pelareorep comes at a time when biopharma M&A is slated to pick up with an “innovation deficit” spurring shopping for new assets. Billions of dollars are obviously available for megadeals, and an endless sea of biotechs are giving shoppers a long list of options.
Biopharmas have $1.7 Trillion to spend on deals this year, and big players like Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions.
Novartis has put out a plea for small biotechs to swim toward its $154 billion pool. Pfizer is eyeing late stage assets with a $175 billion hoard to help boost revenue. And Johnson & Johnson, with a new CEO at the helm, will be "more aggressive" with a $200 billion pile as the company sheds its consumer health unit.
And in this general M&A context can be viewed ONCY's immune platform molecule franchise in which pelareorep + immune checkpoint inhibitors I/O combination therapy in the breast and pancreatic cancer franchises alone, would comfortably suggest a M&A value of USD$ 8 to USD $15 Billion.
Given the $Billions deals already announced and the expected flurry of M&A deals over the next few months, ONCY has been giving shoppers a long list of reasons to be on their lists of companies to be acquired.
Enter James A. Parsons, as ONCY's newest board member.